NanoString Technologies Inc. Initiates Second Clinical Validation Study for Breast Cancer Assay

Published: May 16, 2012

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the initiation of the second clinical validation study of its PAM50-based breast cancer assay. The new study will evaluate samples from more than 1,000 patients enrolled in the Austrian Breast & Colorectal Cancer Study Group 8 (ABCSG8) trial to test the ability of NanoString’s assay to estimate the prognosis of postmenopausal women with hormone receptor-positive early-stage breast cancer.

Back to news